Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367294 | 0.98 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL27925721 | 0.98 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL48723 | 0.98 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL15869337 | 0.98 | MMP2 (0.63) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL26108766 | 0.96 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrazine SCHEMBL28369279 | 0.96 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2285638 | 0.96 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL8070939 | 0.96 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| SCHEMBL28508112 | 0.96 | MMP2 (0.61) | MMP2G6PDCASP7CASP6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28051606 | 0.94 | MMP2 (0.59) | MMP2G6PDCASP7CASP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762365-B1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | AMGEN EUROPE GMBH (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-11639332-B2 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | Amgen (Europe) GmbH (CH) | 2023-05-02 | — | — | US | disclosed |
| CN-114907314-A | Chemical synthesis method of pomalidomide | 浙江工业大学 | 2022-08-16 | — | — | CN | disclosed |
| EP-3762365-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | Amgen (Europe) GmbH (CH) | 2021-01-13 | — | — | EP | disclosed |
| US-20200392082-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | PRO-ONICS PHARMACEUTCIALS LLC | 2020-12-17 | — | — | US | disclosed |
| WO-2019170750-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | CELGENE INTERNATIONAL II SARL (CH) | 2019-09-12 | — | — | WO | disclosed |
| CN-102503876-A | Bisamide derivative, preparation method for same and application thereof | UNIV NANKAI | 2012-06-20 | — | — | CN | disclosed |
| JP-2000128825-A | PRODUCTION OF BIPHENYLTETRACARBOXYLIC ACID | JSR CORP | 2000-05-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392082-A1 | METHODS AND COMPOSITIONS OF ISOINDOLINE-1,3-DIONE AND ISOINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES | PDE4A, PDE3B, PDE4B | MMP2 222/4885G6PD 156/4885CASP7 138/4885 |
| US-11639332-B2 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | PDE4A, PDE3B, PDE4B | MMP2 222/4885G6PD 156/4885CASP7 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.